Abstract:
PROBLEM TO BE SOLVED: To provide an improved HIV protease inhibitor that is very potent, that has reduced side-effects and that is effective against resistant strains of HIV.SOLUTION: This invention relates to: a compound of formula (I) as the HIV protease inhibitor; or a pharmaceutically acceptable salt form, stereoisomer, ester, salt of the ester, prodrug, salt of the prodrug, or combination thereof.
Abstract:
PROBLEM TO BE SOLVED: To provide a large cyclic compound, and to provide a method for using the large cyclic compound. SOLUTION: A pharmaceutical composition is provided. The composition comprises a compound, e.g., tert-butyl(2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diaza cyclopentadecin-6-yl carbamate or its pharmaceutically permissible salt, ester or prodrug, in combination with a pharmaceutically permissible carrier or excipient. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide novel macrocyclic compounds and to provide methods for using the macrocyclic compounds.SOLUTION: The present invention further relates to pharmaceutical compositions comprising compounds, or pharmaceutically acceptable salts, esters or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Abstract:
PROBLEM TO BE SOLVED: To provide a method for producing a macrocyclic compound useful in treating hepatitis C infection.SOLUTION: The present invention provides a method for producing a macrocyclic compound represented by a skeleton of the following formula: 1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide.
Abstract:
PROBLEM TO BE SOLVED: To provide novel macrocyclic compounds, and to provide a method of using the macrocyclic compounds.SOLUTION: The present invention relates to pharmaceutical compositions comprising the compounds represented by the following formula (I) or (I'), or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Abstract:
The invention relates to a novel cyclic hexapeptide having antifungal and antipneumocystic activity as well as pharmaceutical compositions comprising, methods of treating using, and a process for preparing the claimed compounds.
Abstract:
The present invention features compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, and describes methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also describes methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
Abstract:
A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
Abstract:
The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Abstract:
Enantiomerically enriched compounds having the absolute stereochemistry of the formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.